Bio-Techne generates revenue primarily through the manufacturing and sale of high-value life science research products and clinical diagnostics. Its business model relies on a diverse, global customer base comprising academic laboratories, government research institutions, and large-scale pharmaceutical and biotechnology companies. The company makes money by selling high-margin, consumable research reagents—such as recombinant proteins, antibodies, and immunoassay kits—which require constant, recurring purchase by scientists conducting daily experiments. Additionally, they derive significant revenue from the sale of sophisticated, higher-cost laboratory instrumentation, such as their Simple Western protein analysis systems, and from supplying specialized materials for cell and gene therapy manufacturing. By operating across both the early-stage basic research market and the highly regulated clinical diagnostic and industrial therapeutic manufacturing markets, Bio-Techne maintains a diversified, multi-stream revenue model that benefits from global investment in the broader life sciences sector.